- Harry Bloomfield, QC. has been appointed to the board of directors and elected Chairman of the Board of Algernon Pharmaceuticals (AGN)
- Harry J. F. Bloomfield is a lawyer, business manager and philanthropist
- He was appointed Queen’s Counsel in 1991
- Algernon is a clinical-stage pharmaceutical development company
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.10 per share
Algernon Pharmaceuticals (AGN) has elected Harry Bloomfield as a member and Chairman of the Board of Directors.
Harry J. F. Bloomfield is a lawyer, business manager and philanthropist. He received a Bachelor of Arts degree from McGill University, a Bachelor of Civil Law degree from Université de Montréal, and joined the Bar of Quebec. Bloomfield received a Master of Business Administration from the Harvard Graduate School of Business Administration. He was appointed Queen’s Counsel in 1991.
He began his business career on Wall Street with the J. Henry Schroder Banking Corporation in New York. In 1987 he was named to the Board of Directors of the Federal Business Development Bank, now called the BDC (Business Development Bank of Canada) and served for 11 years, 7 of which were as Chairman of the Audit Committee.
Bloomfield has served on numerous boards, both public and private. In May 2011, he was elected to the Board of Directors of Miraculins Inc., a medical diagnostic company, and in April 2012 he was elected the board’s chairman.
“The company welcomes Harry Bloomfield as its newest Board member and Chairman,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
“His extensive background and years of experience in senior business roles will be a tremendous asset to the company as it moves forward executing its exciting and unique drug repurposing business plan.”
Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.10 per share.